Journal articleBioorg Chem2019
Arylboronate prodrugs of doxorubicin as promising chemotherapy for pancreatic cancer.
- Journal
- Bioorg Chem
- Published
- 24 July 2019
- Citations
- 30
- Type
- Article
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
This study describes the synthesis of arylboronate-based ROS-responsive prodrugs of doxorubicin and their biological evaluation as anticancer agents. The determination of the most sensitive cancer type toward arylboronate prodrugs is crucial for further consideration of these molecules in clinical phase. … Excerpt only: this text is the publisher’s. Read it in full at the source.